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Abstract
Background: Constitutively active androgen receptor variants (AR-V) lacking the ligand binding domain (LBD) may promote
the development of castration-resistant prostate cancer (CRPC). The expression of AR-Vs in the clinically most important
metastatic site, the bone, has, however, not been well documented. Our aim was therefore to compare levels of AR-Vs in
hormone-naive (HN) and CRPC bone metastases in comparison to primary PC and non-malignant prostate tissue, as well as
in relation to AR protein expression, whole-genome transcription profiles and patient survival.
Methodology/Principal Findings: Hormone-naı ¨ve (n=10) and CRPC bone metastases samples (n=30) were obtained from
40 patients at metastasis surgery. Non-malignant and malignant prostate samples were acquired from 13 prostatectomized
men. Levels of full length AR (ARfl) and AR-Vs termed AR-V1, AR-V7, and AR-V567es mRNA were measured with RT-PCR and
whole-genome transcription profiles with an Illumina Beadchip array. Protein levels were examined by Western blotting and
immunohistochemistry. Transcripts for ARfl, AR-V1, and AR-V7 were detected in most primary tumors and metastases, and
levels were significantly increased in CRPC bone metastases. The AR-V567es transcript was detected in 23% of the CRPC
bone metastases only. A sub-group of CRPC bone metastases expressed LBD-truncated AR proteins at levels comparable to
the ARfl. Detectable AR-V567es and/or AR-V7 mRNA in the upper quartile, seen in 1/3 of all CRPC bone metastases, was
associated with a high nuclear AR immunostaining score, disturbed cell cycle regulation and short survival.
Conclusions/Significance: Expression of AR-Vs is increased in CRPC compared to HN bone metastases and associated with a
particularly poor prognosis. Further studies are needed to test if patients expressing such AR-Vs in their bone metastases
benefit more from drugs acting on or down-stream of these AR-Vs than from therapies inhibiting androgen synthesis.
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Introduction
Androgens regulate normal prostate tissue growth and differ-
entiation, through activation of androgen receptors in epithelial
and stroma cells, and also play an important role during all phases
of prostate cancer (PC) growth. The standard therapy for patients
with advanced PC is consequently to reduce androgens, either by
surgical or medical castration. After a period of initial remission
tumors eventually relapse, predominantly within the bone, and are
then termed castration-resistant PC (CRPC). The mechanisms
controlling CRPC growth in bone metastases are however largely
unknown and seldom explored by actually examining such
metastases in patients.
Interestingly, the androgen receptor (AR) is commonly active in
CRPC despite castrate levels of circulating testosterone [1,2] and
intense nuclear AR immunostaining in CRPC bone metastases is
related to a particularly short survival [3]. Different mechanisms
have been suggested to contribute to AR activation in CRPC,
including intracrine synthesis of androgens, genetic and epigenetic
changes of the AR making it more sensitive to activation by
androgens or other ligands [1,4,5] and the expression of
constitutively active AR variants (AR-V, see below). These findings
suggest that CRPC could be successfully treated with the novel
drugs now in clinical trials that block androgen synthesis or AR in
metastases (reviewed in [6]), but that constitutively active receptors
could still be a problem. Studies are therefore needed to explore if
these AR-Vs are commonly expressed in CRPC bone metastases
or not.
Structurally the human AR gene is composed of eight exons
encoding a 110 kDa protein consisting of a NH2 terminal trans-
activation domain (NTD), a DNA binding domain (DBD), a hinge
region, and the COOH terminal domain (CTD) which is also the
ligand-binding domain (LBD) [7]. The LBD, encoded by exons 4–
8, is not essential for transcriptional activity [8]. Truncated AR-Vs
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have been detected in PC cell lines as well as in clinical samples,
including benign, malignant and metastatic tissue, as results from
alternative splicing or non-sense mutations of the human AR gene
[9,10,11,12,13,14,15,16,17]. Increased levels of AR splice variants
have been detected in CRPC when compared to hormone-naı ¨ve
(HN) PC [13,14,16]. Those studies included CRPC samples
obtained from primary tumors at surgery, or soft–tissue metastases
and a few bone metastases collected at autopsy. The expression of
AR-Vs in the clinically most relevant metastatic site, the bone, has
not been well documented.
The aim of this study was therefore to analyze expression of the
full length AR (ARfl) and its clinically most abundant splice
variants here termed AR-V1, AR-V7 [14] (also referred to as AR3
[13,17], and AR-V567es [16] in HN and CRPC bone metastases
in comparison to expression in primary PC and in non-malignant
prostate tissue. Moreover, AR transcript levels were related to AR
protein expression, whole-genome transcription profiles and
clinical outcome.
Materials and Methods
Ethics statement
The study was approved by the local ethic review board of
Umea ˚ University and participants gave written or verbal consent.
Patients
Bone metastases were obtained from a series of fresh-frozen and
formalin fixed paraffin embedded biopsies collected from patients
with PC operated for metastatic spinal cord compression or
pathologic fractures at Umea ˚ University Hospital (2003–2009).
These patients have been thoroughly described in [3] and clinical
characteristics and therapies are summarized in Table 1. The
study also includes 13 patients who were treated with radical
prostatectomy at Umea ˚ University Hospital, between Feb 2005
and Sep 2006. Median age for the patients was 60 years (range 48–
68 years) and median PSA were 6.6 ng/ml (range 3.5–24 ng/ml).
Eleven of the patients had tumors graded as Gleason score (GS) 7
and two as GS 8. Four of the tumors were in stage T2 and nine in
stage T3. Immediately after surgical removal the prostates were
brought to the Pathology department and cut in 0.5 cm thick
slices. From these slices 20 samples were punched from each
prostate using a 0.5 cm steel cylinder and frozen in 270uC within
30 minutes after surgery. The prostate slices were then fixed in 4%
formaldehyde for 24 h, dehydrated, embedded in paraffin, cut in 5
micron thick sections and stained with hematoxylin-eosin. The
nature of the frozen tissue samples (non-malignant or malignant)
was determined by their location in the whole-mount sections, but
also verified by light microscopy of hematoxylin/eosin-stained
cryostat section from each of the tissue samples analyzed as
described below. In these sections the percentage of tumor tissue
was quantified and the tumor GS determined.
Tissue preparation and RNA extraction
Representative areas of bone metastases, primary PC and non-
malignant prostate tissue were cryo-sectioned into extraction tubes
and RNA was isolated using the Trizol protocol (Invitrogen,
Stockholm, Sweden). The percentage of tumor cells in the samples
varied between 25–95%. The RNA concentrations were quanti-
fied by absorbance measurements using a spectrophotometer (ND-
1000 spectrophotometer; NanoDrop Technologies, Inc., Wilming-
ton, DE). The RNA quality was analyzed with the 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and
verified to have a RNA integrity number $6.
Real time RT-PCR
Two-hundred (200) ng of RNA were reversed transcribed with
Superscript II reverse transcriptase (Invitrogen) in a total volume of
Table 1. Clinical characteristics of patients with prostate cancer bone metastases obtained at orthopedic surgery.
Clinical characteristics Hormone-naı ¨ve n=10 Castration-resistant
a n=30
Age at PCa diagnosis (yrs) 79 (60–85) 70 (51–86)
Age at surgery (yrs) ¨ 73 (54–88)
Serum PSA at diagnosis (ng/ml) 156 (21–10000) 71 (2–2558)
Serum PSA at surgery (ng/ml) ¨ 335 (4–5139)
Androgen deprivation therapy prior to surgery
Castration
b -2 0
Castration plus anti-androgen
c -1 0
Radiation prior to surgery
d
Yes 0 4
No 10 26
Chemotherapy prior to surgery
Yes 0 2
No 10 28
Follow-up after surgery
e (months) 26 (0–66) 4.5 (0.25–35.50)
Continuous values are given as median (min–max values).
aCastration-resistant patients had disease progression after long-term androgen deprivation therapy.
bIncludes surgical ablation, LHRH/GNRH agonist therapy, and therapy with anti-androgens (casodex, flutamide), but specifically no anti-androgens at the time for
orthopedic surgery.
cCastration therapy as stated above and anti-androgen therapy (casodex) at the time for orthopedic surgery.
dRadiation towards operation site.
eThe time between date of operation and the latest follow-up examination or death.
doi:10.1371/journal.pone.0019059.t001
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Biorad iQ5 iCycler (Bio-Rad Laboratories, Hercules, CA).
Reactions were done in a 20 ml volume using the IQ SYBR Green
Supermix (Bio-Rad laboratories). The following primer sets were
used; ARfl: 59-CCATCTTGTCGTCTTCGGAAATGTTAT-
GAAGC-39 and 59-AGCTTCTGGGTTGTCTCCTCAGTGG-
39, AR-V1: 59-CCATCTTGTCGTCTTCGGAAATGTTATG-
AAGC-39 and 59-CTGTTGTGGATGAGCAGCTGAGAG-
TCT-39, AR-V7: 59-CCATCTTGTCGTCTTCGGAAATGT-
TATGAAGC-39 and 59-TTTGAATGAGGCAAGTCAGCC-
TTTCT-39, and AR-V567es: 59- CCAAGGCCTTGCCTGA-
TTGC and 59-TTGGGCACTTGCACAGAGAT-39, resulting in
amplicons of 143, 145, respectively 125 bp, as previously described
[14,16]. Primers for the housekeeping gene RPL13A (59-
GTACGCTGTGAAGGCATCAA-39 and 59- GTTGGTGTTC-
ATCCGCTTG-39) amplified a 125 bp fragment. Each sample was
run in duplicates and adjusted for corresponding RPL13A levels.
Melting curve analysis confirmed the amplified products, which
were also analyzed by 1% agarose gel electrophoresis to confirm the
expected size (data not shown).
Western blot analysis
Fresh-frozen bone metastases and prostate samples were cryo-
sectioned and proteins were extracted from 20 sections (10 mm
each) using the AllPrep Mini kit, according to the manufacturer’s
instructions (Qiagen, Hilden, Germany). Protein concentration
was determined by the BCA Protein assay (Pierce Chemical Co.,
IL, USA). 22RW1 cells were maintained according to manufac-
turer’s instructions (ATCC) and proteins were extracted as
previously described [18].
Samples(20 mg protein) were separated by 7.5SDS-PAGE under
reducing conditions and subsequently transferred to PVDF
membranes (Immobilon-P, Millipore, Billerica, MA). The mem-
branes were stained with Ponceau red to confirm equal sample
loading and transfer (results not shown). Membranes were then
blocked in5%milkfollowedbyanti-AR antibodyincubations;N-20
(diluted 1:500, Santa Cruz Biotechnology, Santa Cruz, CA) or PG-
21 (diluted 1:1000, Upstate, Lake Placid, NY) in order to detect the
ARfl and AR-Vs, and C-19 (Santa Cruz) in order to detect ARfl but
not AR-Vs lacking the LBD. Primary antibodies were diluted in 1%
milk/PBST and incubated in 4uC over night. The secondary anti-
rabbitIgG(Dako,Glostrup,Denmark)antibody(diluted1:20000in
2.5% milk) was applied after washing in PBST and incubated for
1 h inRT.Proteinexpression wasvisualized afterextensivewashing
using the ECL Advanced detection kit (GE Healthcare, Buck-
inghamshire,UK)andquantifiedwitha ChemiDocscannerandthe
Quantity One 4 software (Bio-Rad Laboratories).
Immunohistochemistry
The bone metastases examined in this study have been previously
immunostained for the AR, Ki67 (cell proliferation), activated
caspase 3 (apoptotic cells) and PSA antigens (Table 2) following
protocols described before [3]. Nuclear AR and cytoplasmic PSA
immunostaining were scored according to intensity (0, 1, 2, or 3)
and fraction of stained cells (0, 1, 2, 3, or 4). A total score (ranging
from 0–12) was obtained by multiplying the staining intensity and
fraction scores. A total AR score of 8 or above (median and above)
was previously defined as high and found to be associated with a
shorter survival after orthopedic metastasis surgery than a AR total
score below 8 [3]. A PSA score of 8 and below (median and below)
was associated with an unfavorable outcome in CRPC patients [3].
The fractions (%) of Ki67 and active caspase 3 stained tumor cells
were previously determined and found not to be associated with
outcome in this patient material [3].
Gene expression analysis
Two-hundred-fifty (250) ng of total RNA per sample was used for
cRNA production by the Illumina TotalPrep RNA amplification kit
(Ambion Inc, St. Austin, TX, USA) according to the provided
protocol. The quality of cRNA was evaluated using the RNA 6000
pico kit (Agilent Technologies) and the Agilent 2100 Bioanalyzer
(Agilent Technologies). A total of 750 ng cRNA was used for
hybridization to a human HT12-v3 Illumina Beadchip gene
expression array (Illumina, San Diego, CA, USA), including
48803 probes and 37846 annotated genes, according to the
manufacturer’s protocol. The arrays were scanned and fluorescence
signals obtained using the Illumina Bead Array Reader (Illumina,
San Diego, CA, USA). Array data analysis was performed with
GenomeStudio software (version 2009.1, Illumina). Samples were
normalized by the cubic spline algorithm and probes with all signals
lower than two-times the mean background levels were excluded
from the analysis. Differentially expressedgenes were identifiedwith
the Mann-Whitney differential expression algorithm (P,0.05) and
defined to have a fold change in-between groups greater than 1.5.
Gene ontology analysis was done with the Metacore software
(GeneGoInc. St. Joseph, MI, USA).
Statistical analysis
Correlations between variables were analyzed using the Spear-
man rank test. Groups were compared using the Mann-Whitney U
test for continuous variables and the Chi-square test for categorical
variables. Kaplan-Meier survival analysis was performed with death
of PC as event and follow-up time as time between metastasis
surgery and the latest follow-up examination. Statistical analyses
wereperformed usingtheStatisticalPackageforthe SocialSciences,
SPSS 17.0 software (SPSS, Inc, Chicago, USA). A P-value less or
equal to 0.05 was considered statistically significant.
Results
High mRNA levels of AR splice variants in CRPC bone
metastases
Transcripts for the normal ARfl and the most abundant AR
splice variants known so far [16]; AR-V1, AR-V7, and AR-
Table 2. Immunohistochemical data of castration resistant
bone metastases stratified according to expression of AR
splice variants (AR-V).
AR-V high
a,d
(n=10)
Other
a,d
(n=20)
AR score
b 12 (8–12)* 8 (0–12)
PSA score
c 6 (0–12)* 9 (1–12)
Ki67 index (%) 19 (11–33) 13 (3.5–44)
Apoptosis index (%) 2 (0.3–4.0) 1.3 (0.3–3.3)
Continuous values are given as median (min–max values).
aAR-V high bone metastases were defined to have detectable levels of the
AR-V567es transcript and/or the AR-V7 transcript levels in the upper quartile
while other CRPC bone metastases had lower AR-V mRNA levels.
bAn AR score of 8 or above was defined as high and associated with a
particularly short survival after orthopedic surgery [3].
cA PSA score of 8 and below (median and below) was associated with an
unfavorable outcome in CRPC patients [3].
*P#0.05 according to Chi-square test.
dPatients with AR-V high bone metastases were not statistically different from
other patients with bone metastases regarding any of the clinical characteristics
in Table 1.
doi:10.1371/journal.pone.0019059.t002
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malignant and GS7-8 tissue parts of primary prostate tumors
and in bone metastases samples, using real-time RT-PCR analysis.
As shown in Table 3, the ARfl, AR-V1, and AR-V7 transcripts
were detected in most of the non-malignant, primary tumor, and
metastases samples examined, while the AR-V567es transcript was
detected in 7 (23%) of CRPC bone metastases only.
There was a tendency for higher levels of ARfl, AR-V1, and
AR-V7 mRNA in HN bone metastases than in primary PC tissue,
but the differences were non-significant (Figure 1). Clearly elevated
ARfl, AR-V1 and AR-V7 transcript levels were however seen in
the CRPC bone metastases, which showed 8, 44, respectively 120
times higher median levels than the HN metastases (P#0.001,
Figure 1). The ARfl, AR-V1, and AR-V7 mRNA levels in the non-
malignant prostate samples were comparable to levels in the
primary prostate tumors (Figure 1).
Expression of LBD-truncated AR protein variants in CRPC
bone metastases
Proteins levels of AR-Vs were examined using Western blot
analysis of 13 samples of CRPC bone metastases randomly selected
to represent cases with high AR-V7 mRNA levels (levels in the
upper quartile, Q4), cases with low and intermediate levels of AR-
V7 mRNA (levels in the lowest; Q1, and intermediate; Q2–Q3,
quartiles respectively) as well as detectable/non-detectable levels of
AR-V567es mRNA (Figure 2). The 22Rv1 cell line known to
express the AR-V7 variant [13], but also additional splice variants
[15] served as a positive control. A primary prostate sample with
undetectable AR-V7 mRNA served as a negative control (Figure 2).
Protein bands with the expected molecular weights of about
110 kDa (ARfl) and 80 kDa (presumingly AR-V1, AR-V7 or
-V567es) were detected in CRPC bone metastases, by antibodies
targeting the N-terminal domain of the AR, while the 80 kDa AR-
Vs were not detected using the antibody targeting the C-terminal
LBD domain (Figure 2A). The most intense 80 kDa bands were
detected in samples with Q4 AR-V7 mRNA levels, while CRPC
bone metastases with lower AR-V7 mRNA levels showed lower to
undetectable levels regardless of corresponding AR-V567es mRNA
levels (Figure 2B). Based on blot intensities, the AR variant proteins
constituted in median 32% of the ARfl protein level (range 0 to
95%, n=13, data not shown).Thiswas in contrast to corresponding
ratios on the RNAlevel where the AR-V7 and AR-V567 transcripts
represented in median only 0.4% (range 0.03 to 7%, data not
shown) and 1.0% (range 0.3 to 1.2%, data not shown), respectively,
of the ARfl mRNA level, according to difference in RT-PCR ct
levels. Our results thus indicate that AR-Vs lacking the LBD
domain are possible post-transcriptionally stabilized in CRPC bone
metastases in relation to the ARfl.
Expression of AR-V7 and AR-V567es mRNA is associated
with a poor prognosis
The AR-V1, AR-V7, and ARfl mRNA levels were correlated in
all samples examined (data not shown, n=66) and in the sub-
group of CRPC bone metastases (AR-V1 vs. AR-V7; Rs=0.91,
P,0.001, AR-V1 vs. ARfl; Rs=0.47, P,0.01, and AR-V7 vs.
ARfl; Rs=0.58, P,0.001, n=30). Bone metastases with detectable
AR-V567es mRNA had about 3-fold higher ARfl median mRNA
level than the other CRPC metastases (P=0.004).
Patients with AR-V7 mRNA levels in Q4 had significantly
shorter cancer-specific survival after metastasis surgery than the
other CRPC patients and a similar outcome was seen for patients
with detectable levels of the AR-V567es in comparison with the
rest (Figure 3A–B). Ten patients with CRPC bone metastases were
either included in the AR-V7 Q4 sub-group and/or had
detectable levels of the AR-V567es, and are further referred to
as AR-V high patients. The AR-V high patients had a median
survival time after metastasis surgery of only 2 months as
compared with 8 months for the rest of the CRPC patients
(Figure 3C). No association was found between ARfl or AR-V1
mRNA levels and survival after metastasis surgery (data not
shown).
Metastases with high levels of the AR splice variants
show intense nuclear AR immunostaining
As we have previously found that high AR immunostaining
scores were associated with a particularly short survival after
metastasis surgery and now that AR-V high patients had a poor
prognosis, we wanted to examine if high AR staining score was
associated with levels of AR-Vs. The AR-V high metastases all had
high AR staining scores in comparison with other CRPC bone
metastases which showed variable staining ranging from weak to
strong (Table 2, P=0.02).
Furthermore, AR-V high metastases showed significantly lower
PSA immunostaining score (Table 2, P=0.038) and tendencies of
having higher fractions of proliferating and apoptotic tumor
epithelial cells (P=0.12 and P=0.085, respectively) than other
CRPC metastases (Table 2).
Expression of AR splice variants is associated with
disturbed cell cycle control
The gene expression profile of the sub-group of AR-V high
bone metastases was compared to the profile of other CRPC bone
metastases, by using an Illumina based cDNA array including
48803 gene probes. About 17700 probes were defined to give
signals above background in the PC bone metastases. One
hundred and ninety-five (195) probes were differentially expressed
between the AR-V high bone metastases and other CRPC bone
Table 3. Detection of the full length androgen receptor (ARfl) RNA transcript and AR splice variants in prostate tissue and bone
metastases.
AR variant
Non-malignant prostate
tissue (n=13)
Primary prostate
tumors (n=13)
Hormone-naı ¨ve bone
metastases (n=10)
CRPC bone metastases
(n=30)
ARfl 100% 92% 100% 100%
AR-V7
a 85% 77% 80% 100%
AR-V1
a 54% 69% 90% 100%
AR-V567es
b 0% 0% 0% 23%
aAR variants V1 and V7 [14].
bAR variant V567es [16].
doi:10.1371/journal.pone.0019059.t003
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PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e19059Figure 1. Normalized mRNA levels of the A) full length androgen receptor (ARfl), B) AR-V1 [14], and C) AR-V7 [14] in a total of 66
tissue samples from prostate cancer patients. All mRNA levels were adjusted for corresponding housekeeping gene (RPL13a) mRNA levels,
normalized to the median value for the primary tumors samples, and transformed by the natural logarithm. Levels in non-malignant prostate tissue
(n=13), primary prostate tumor (n=13), hormone-naı ¨ve bone metastases (n=10), and castration-resistant bone metastases (n=30) samples are
shown in white, light grey, dark grey, and black, respectively. Undetectable levels are not indicated, but represented by columns symbolizing the
lowest measurable level in RT-PCR analysis of each transcript variant.
doi:10.1371/journal.pone.0019059.g001
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groups (P,0.05) and further included in ontology analysis for
evaluation of enriched processes. Many (60) of the differentiating
gene products were proposed to be directly interacting via the AR,
C-MYC, and CDK1 proteins (Figure 4 and Table S1). C-MYC
and CDK1 are two key regulators of the cell cycle and,
accordingly, the top 5 enriched process networks found in AR-V
high bone metastases were; Cell cycle Core, Cell cycle S phase,
Cell cycle Mitosis, Cytoskeleton spindle microtubules and Cell
cycle G2-M. C-MYC and CDK1 are also pro-survival factors
inhibiting apoptosis and in addition we found increased transcript
levels of the anti-apoptotic proteins survivin and BCL2L12 in the
AR-V high compared to the other CRPC bone metastases
(Figure 4). Notably, however, levels of other key regulators of
apoptosis, such as death receptors, BAX, BCL2, and caspases were
not significantly changed and, furthermore, apoptosis-related
process networks were not significantly enriched in our data (data
not shown). Several gene transcripts known to be positively
regulated by the AR were found at high levels in the AR-V high
metastases, such as CDK1, CYCLINA2, HSP27, C-MYC,
UGT2B17, CDC20, UBE2C, while others such as KLK3 (PSA),
KLK2, NKX3-1, FKBP5 and TMPRSS2 were not (Figure 4).
Discussion
This paper describes, for the first time, the expression pattern of
the LBD-truncated AR splice variants AR-V1, AR-V7 [14] and
AR-V567es [16] in PC bone metastases in patients and,
furthermore, that levels of those variants are increased in CRPC
bone metastases and that expression of the AR-V567es and/or
very high levels of the AR-V7 is found in individuals with
particularly poor prognosis.
Several structurally different, constitutively active AR-Vs have
been identified so far in clinical PC samples [10,11,13,14,16,17],
and we here show enrichment of LBD-truncated AR splice variants
in PC bone metastases. In contrast to Sun and co-workers, who
found the AR-V567es to be the most abundant splice variant
examined [16], we found the AR-V7 to be more commonly
expressed than the AR-V567es in CRPC. This disparity could
possibly be technically explained by different sensitivities of the RT-
PCR techniques used, but could possibly also reflect heterogeneities
inARsplicevariant expression between differenttissueoriginsaswe
examined CRPC in bone while Sun et al included CRPC from
various sites. We also importantly noted that several of the
examined CRPC bone metastases (AR-V high cases) expressed
LBD-truncated AR proteins at levels comparable to the ARfl
protein levels, even though the corresponding AR variant
transcripts were found at relatively much lower levels than the
ARfl mRNA. A post-transcriptional stabilization of AR splice
variants inrelation to the ARfl in selective CRPC bone metastasesis
therefore plausible, although the mechanism for this is not known.
The poor prognosis of patients with CRPC metastases
expressing the AR-V567es and/or high levels of AR-V7
transcripts are probably related to the postulated constitutive
activity of these variants. The AR-V567es contains the nucleus
localization sequence (NLS) of the hinge region in exon 4 [16] and
the AR-V7, in contrast to AR-V1, have been postulated to contain
a NLS in its cryptic exon [14]. Accordingly, the AR-V7 and AR-
V567es have been shown to translocate into the nucleus, bind to
AR responsive elements, and activate/suppress gene transcription
in vitro without the need for ligand binding [14,16,17]. Interest-
ingly, Watson and co-worker recently showed an instant increase
of AR-V7 and AR-V1 mRNA levels in xenograft models for PC
after castration, as well as a decrease after androgen supplemen-
Figure 2. Western blot analysis of the full length androgen receptor (ARfl) and ligand binding domain (LBD) truncated AR variants
in castration resistant prostate cancer (CRPC) bone metastasis samples. A) Antibodies (N-20 and PG-21) targeting the N-terminal domain
(NTD) of the AR detected the ARfl and AR variants (AR-V; presumingly AR-V1, AR-V7, and/or AR-V567es). Antibody C-19 targeting the LBD detected
the ARfl of ,110 kDa, but not the LBD-truncated AR variants of approximately ,80 kDa. B) Analysis of CRPC bone metastases representing samples
with high levels of AR-V7 mRNA (levels in the highest quartile, Q4, according to RT-PCR analysis), as well as samples with AR-V7 mRNA levels in Q1,
Q2, and Q3, by using the N-20 antibody. 22Rv1 cell extract served as positive control for ARfl and ,80 kDa AR variants and a primary prostate cancer
sample (P) served as negative control for the AR variants.
doi:10.1371/journal.pone.0019059.g002
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androgens and thus probably induced in patients shortly after
castration therapy [17]. It is tempting to speculate that those and
other AR-Vs will be selected for also during the development of
castration-resistant disease and thereby contribute to relapse from
therapies aiming to reduce steroid levels or ligand binding to the
normal AR. Accordingly, we found higher levels of the AR splice
variants in CRPC than in HN bone metastases. The AR-V1 and
AR-V7 transcripts were however detected also in a substantial part
of the non-malignant and malignant radical prostatectomy
specimens, although at a lower level than in the bone metastases,
and others have shown that levels of AR-V7 (AR3) in primary
prostate tumors were predictable for outcome after radical
prostatectomy, with a shorter time to chemical relapse in
individuals with higher levels [13,14]. The reason to this is not
known, but indicates that constitutively active AR-Vs could be
part of the normal prostate physiology and that a selection of those
variants occurs during PC progression.
The enrichment of structurally different, constitutively active
AR-Vs during the development of CRPC metastases points out
complex and heterogeneous molecular events which by difference
means seem to ensure AR activation in the absence of testicular
androgens. Patients expressing constitutively active AR-Vs will in
the long-term probably not benefit from anti-androgen therapies
aiming to reduce steroid synthesis, such as surgical castration,
LHRH analogs, or the newly introduced agent abiraterone that
inhibits CYP17 and thereby steroid synthesis not only in testis but
also in the adrenal glands and in tumor tissue [19,20].
Surprisingly, the novel AR antagonist MDV3100 targeting the
LBD of the ARfl and currently in clinical trials for CRPC [21,22]
were found to inhibit castration-resistant growth induced by the
expression of constitutive AR-V7 in an animal model for PC [17].
This is encouraging as novel AR antagonists inhibiting receptor
translocation into the nucleus thus may have therapeutic effects
also in patients expressing constitutively active AR-Vs. Not all
CRPC patients do however respond to the abiraterone and
Figure 3. Kaplan-Meier analysis of androgen receptor (AR) variant transcript levels in bone metastasis samples from castration-
resistant prostate cancer (CRPC) patients versus cancer-specific survival after metastasis surgery. Patients with A) AR-V7 [14] mRNA
levels in the highest quartile (Q4), B) detectable AR-V567es [16] mRNA levels, and C) detectable AR-V567 and/or AR-V7 Q4 (AR-V high) mRNA levels
had shorter survival than other patients with CRPC disease.
doi:10.1371/journal.pone.0019059.g003
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within a few months [20,22]. If this kind of therapy resistance is
related to expression of constitutively active AR-Vs in bone
metastases (the primary target for the therapy) is currently not
known and cannot be determined until clinical studies starts to
include biopsies from bone metastases. Furthermore, therapeutic
agents inhibiting those AR-Vs or their down-stream effects need to
be developed [23,24]. Another possible explanation for resistance
to castration therapy is the presence of AR negative tumor cells,
and thus AR by-pass during tumor progression [25]. Complete
lack of AR expression is found only in a small sub-population of
CRPC bone metastases, but AR negative tumor cells scattered
among the positive are found in most CRPC bone metastases [3],
and thus emphasis the need also for therapies not relying only on a
functional AR.
In the clinical samples examined in the present study, detectable
levels of the AR-V567es and/or high levels of the AR-V7
transcripts were associated with deregulated levels of known AR-
controlled genes, but specifically not of some classical androgen
regulated genes such as KLK3 (PSA), TMPRSS2, and FKBP5
which were induced by over-expression of AR-V7 or AR-V567es
in LNCaP cells in vitro [14,16]. Accordingly, the AR-V high cases
showed less PSA immunostaining than other CRPC metastases.
Instead we found gene transcript levels which differentiated AR-V
high bone metastases from other CRPC bone metastases by
indicating high C-MYC and CDK1 activity, and a disturbed cell
cycle control regarding G1-S as well as G2-M transition despite a
non-significant increase in Ki67 labeling. The development of
CRPC has been characterized by an unbalanced proliferation to
apoptosis ratio and resistance to apoptotic stimuli [26,27]. In the
late stage of disease examined in this study we did not however,
with a few exceptions, find any clear-cut signs of altered expression
of apoptosis-regulating genes or a further deregulation of the
apoptotic process in AR-V high compared to other CRPC bone
metastases. Based on our data, we are not able to discriminate if
the disturbed cell cycle control found in the AR-V high bone
metastases is truly related to the expression of the AR-Vs, the
ARfl, or just associated with the particularly advanced disease in
Figure 4. Network of directly interacting gene products of differentially expressed genes between the AR-V high (detectable AR-
V567 and/or AR-V7 in the highest quartile, Q4) and other castration-resistance prostate cancer (CRPC) bone metastases (P#0.05
and fold change $1.5), generated by Metacore
TM (Genego Inc, USA) bioinformatics analysis. Red circles indicate higher and blue circles
indicate lower transcript levels in the AR-V high than in other CRPC bone metastases. Note that many of the differentiating gene products are directly
interacting via AR, C-MYC and CDK1.
doi:10.1371/journal.pone.0019059.g004
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biological processes deregulated in cases with high expression of
constitutively AR-Vs could be useful in the development of novel
therapies for CRPC. For example, the C-MYC protein could be a
therapeutic target in selective patients with PC as already
suggested [28].
In conclusion, LBD-truncated AR-Vs are frequently expressed
in bone metastases, with higher levels in CRPC than in HN cases.
Furthermore, transcript levels of the constitutively active AR-V7
and AR-V567es seem to be associated with high nuclear AR
immunostaining scores, disturbed cell cycle control, and particu-
larly poor prognosis within the group of CRPC patients. This
conclusion is however based on a limited number of patients and
results must therefore be verified in other studies. If the results hold
true patients expressing high levels of AR-V7 and AR-V567es
probably will need to be treated with drugs acting on or down-
stream of the AR-Vs rather than with drugs inhibiting androgen
synthesis.
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